You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
THIS SBIR PHASE I CONTRACT IS FOR A WEARABLE ALCOHOL BIOSENSOR THAT QUANTIFIES BAC IN REAL TIME.
SBC: DeLeon, Augustina S Topic: NIAAATechnology validation study of a wearable NIR spectrometer to quantify BAC in real time
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Electrochemical aptasensor for Anti-Tuberculosis antibiotic quantification
SBC: GUILD ASSOCIATES INC Topic: NIAIDSpecific AimsIn Phase I of this SBIRwe will complete three specific aimssynthesize stable combination adjuvant formulations that are compatible with an HVLP antigenidentify the combination adjuvant properties that augment the safe and durable immunity to Handdemonstrate the superior protective benefit of the new combination adjuvant over existing adjuvant solutions for pandemic influenza vaccinesI ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
TOPIC 396- IMAGING FOR CANCER IMMUNOTHERAPIES-MOONSHOT
SBC: COLUMBUS NANOWORKS, INC. Topic: NCIIn vivo imaging of cells labeled with fluorescent nanodiamondsFNDsis a new way of monitoring immune cells during cancer immunotherapyFNDs are non toxicinfinitely photostable nanomaterials that are easily conjugated with antibodiesand emit fluorescence in the near infrared spectral regionIn this Phase I SBIRwe will use a murine melanoma model and outline a plan to use FNDs for imaging immunosupress ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
TOPIC 369: NOVEL DOSING AND DISPENSING SYSTEM FOR MULTIPARTICULATE CANCER DRUGS
SBC: HS-DESIGN, INC Topic: NCIOncology drugs continue to advance at a rapid pace with many therapies delivered orally as tablets or capsulesSmaller childrenhowevercannot swallow tablets or capsulesFor these drugs to be used in the pediatric population they need to be reformulatedTraditionally this has meant creating a liquid suspensionchewableor rapid dissolve tabletCancer medicationshoweveroften have terrible taste profiles t ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
TOPIC 393: BREATH TEST FOR BIOMARKERS OF RADIATION EXPOSURE
SBC: MENSSANA RESEARCH INC Topic: NCIThe problemPatients receiving therapeutic radiation are at risk of adverse toxic effectsThese adverse events are usually unpredictable and may result in severe morbidity or mortalityExampleA third or more of patients receiving chest radiation for cancers of lung may develop life threatening acute radiation pneumonitisThe clinical needThere is a clinical need for an objective test to estimate the b ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Radiation Sterilizable, RFID Tagged Vials for Biomedical Samples
SBC: BIOTILLION LLC Topic: ODAbstract The Specific Aim of this Phase IIb (Phase II competitive renewal) SBIR proposal is to advance the prototypes we developed under our Phase I and II SBIR grants into commercial production. We will produce SBS-96 format radiation sterilizable electronically tagged sample vials that can be read at ultra-low temperatures. Hundreds of millions of SBS-96 vials are sold each year and each of thes ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Advancing ARP-1536, an Anti-VE-PTP Antibody, as an Adjunctive Therapy for the Treatment of Sight-Threatening Retinopathies
SBC: Aerpio Therapeutics LLC Topic: NEIAbstract Diabetic macular edemaDMEis the leading cause of vision loss in the working age population whichconsidering the worldwide epidemic of diabetesrepresents a growing socioeconomic challengeDME is characterized by the destabilization of retinal blood vessels resulting in the accumulation of fluid in the maculathe area of the retina responsible for central visionThe current standard of care fo ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Well-Flushed Hydrodynamic Bearing for Miniature Blood Pumps
SBC: Perfusion Solutions, Inc. Topic: NHLBIVentricular assist devicesVAD sclearly have a role in cardiac medicinehow to precisely define that role is still subject to research and debateconsidering the possibilities of destination therapybridge to transplantbridge to recoverybridge to definitive therapy and possibly other variants one might specifyCertain VAD features are emerging as requiredadequate output to truly make a difference to th ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Software for OCT Analysis of Vascular Stents
SBC: DYAD MEDICAL, INC. Topic: NHLBIProject Summary. Dyad Medical, Inc. will create intravascular Optical Coherence Tomography (IVOCT) software for clinical, live time determination of stent apposition and for offline analysis of stent implantation. Every year, 100s of thousands of patients in the US are treated with intravascular stents creating an opportunity for both solutions. Although advancements such as drug eluting metal ste ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Novel carcinoma-specific monoclonal antibodies for therapies and diagnostics
SBC: Recodagen LLC Topic: 102Problems that cause significant negative impacts on cancer patientsandaposquality of life and on their survival include current therapies that lead to unwanted side effects due to their action on normal cellsFurthermoreinvading carcinoma cells can be resistant to therapies due to the migration proliferation dichotomyMonoclonal antibodyMabtherapiessuch as those against EGFVEGFc Met and their respec ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health